Literature DB >> 10609688

Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype.

A Wallin1, K Blennow, L Rosengren.   

Abstract

There is a need for improvement of the diagnosis of vascular dementia (VaD). Today, the clinician has to rely on clinical examination, history, and, possibly, brain imaging to identify cerebrovascular damage and other signs of VaD. The clinical diagnosis of subcortical VaD may be difficult because the clinical manifestation of this disorder is often similar to that of Alzheimer disease. There are also mixed forms of the two disorders. Biochemical diagnostic markers, which reflect the pathogenetic processes in the brain, would add to the accuracy of the diagnosis. There are some interesting candidate markers: the cerebrospinal fluid (CSF)/serum albumin ratio could be used to identify blood-brain barrier damage to the small intracerebral vessels, CSF sulfatide to identify ongoing demyelination of the white matter, CSF neuron-specific enolase to identify ongoing neuronal degeneration, and CSF tau protein and CSF neurofilament light protein to identify ongoing axonal degeneration. None of these potential markers is specific to subcortical VaD, but together and used in conjunction with the conventional diagnostic workup, they may be of diagnostic value.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10609688

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  11 in total

1.  Blood-brain barrier permeability abnormalities in vascular cognitive impairment.

Authors:  Saeid Taheri; Charles Gasparovic; Branko N Huisa; John C Adair; Elaine Edmonds; Jillian Prestopnik; Mark Grossetete; N Jon Shah; John Wills; Clifford Qualls; Gary A Rosenberg
Journal:  Stroke       Date:  2011-06-30       Impact factor: 7.914

2.  Jobelyn® Supplement Lowered Neuronal Degeneration: Significance of Altered p53 and ɤ-Enolase Protein Expressions in Prefrontal Cortex of Rat Exposed to Ethanol.

Authors:  Oyinbo A Charles; Igbigbi S Patrick; Avwioro O Godwin
Journal:  Ann Neurosci       Date:  2016-09-09

3.  Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials.

Authors:  Gary A Rosenberg; Jillian Prestopnik; John C Adair; Branko N Huisa; Janice Knoefel; Arvind Caprihan; Charles Gasparovic; Jeffrey Thompson; Erik B Erhardt; Ronald Schrader
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-24       Impact factor: 10.154

4.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

Review 5.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 6.  Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment.

Authors:  Gary A Rosenberg; Maria Bjerke; Anders Wallin
Journal:  Stroke       Date:  2014-04-01       Impact factor: 7.914

7.  An overview of biomarkers in Alzheimer's disease.

Authors:  Pandurang R Wattamwar; P S Mathuranath
Journal:  Ann Indian Acad Neurol       Date:  2010-12       Impact factor: 1.383

Review 8.  Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-22       Impact factor: 6.200

Review 9.  Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.

Authors:  Yu Yamazaki; Takahisa Kanekiyo
Journal:  Int J Mol Sci       Date:  2017-09-13       Impact factor: 5.923

10.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.

Authors:  Daniel A Nation; Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Lina M D'Orazio; Maricarmen Pachicano; Farshid Sepehrband; Amy R Nelson; David P Buennagel; Michael G Harrington; Tammie L S Benzinger; Anne M Fagan; John M Ringman; Lon S Schneider; John C Morris; Helena C Chui; Meng Law; Arthur W Toga; Berislav V Zlokovic
Journal:  Nat Med       Date:  2019-01-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.